Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells $645,483.52 in Stock

by · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at $25,141,737.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

  • On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total value of $663,874.53.
  • On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.
  • On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The stock was sold at an average price of $105.16, for a total transaction of $277,412.08.
  • On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The stock was sold at an average price of $111.66, for a total transaction of $613,683.36.
  • On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The shares were sold at an average price of $108.10, for a total value of $4,053,750.00.

Natera Price Performance

NTRA stock opened at $127.78 on Friday. Natera, Inc. has a one year low of $36.90 and a one year high of $132.01. The firm has a 50-day moving average of $114.45 and a two-hundred day moving average of $105.43. The firm has a market capitalization of $15.69 billion, a PE ratio of -40.96 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the previous year, the company posted ($0.97) earnings per share. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. TD Cowen increased their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Morgan Stanley lifted their target price on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Robert W. Baird upped their price target on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. Finally, UBS Group dropped their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $120.07.

Read Our Latest Stock Analysis on Natera

Institutional Investors Weigh In On Natera

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in shares of Natera by 1,073.1% during the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after purchasing an additional 60,127 shares in the last quarter. Thematics Asset Management increased its position in Natera by 3.1% during the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after buying an additional 2,738 shares during the last quarter. Crestline Management LP raised its holdings in Natera by 16.0% during the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after buying an additional 8,997 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after buying an additional 9,781 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its position in shares of Natera by 289.7% in the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after buying an additional 632,047 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading